Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bristol Stresses Cost Control Despite Strong Earnings Quarter

Executive Summary

Pharma pledges level operating expenses from 2016 to 2020, despite a planned uptick in 2017 R&D spend. Sales were strong almost across the board for Bristol during the third quarter, but headwinds are coming, especially in immuno-oncology.


Related Content

Bristol Closes, Consolidates R&D Sites Under Cost-Containment Plan
Deal Watch: Bristol Leaves Neuropathic Pain Candidate To Lexicon
Bristol Still Rules Immuno-Oncology, But For How Long?
Bristol Still Rules Immuno-Oncology, But For How Long?
Bristol's HCV Bump Catalyzes Strong Quarter, But Not Expected To Last
Gilead's Epclusa Approved As First Pan-Genotypic HCV Therapy
Bristol-Myers Boosted By Opdivo Sales, Growth Prospects


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts